骨髓介质干细胞移植的最佳剂量用于实验性性结肠炎
Xiaoyun Chen1, Yan Xia2, Min Min3
1Department of Pathology, Wuhan No.1 Hospital, Wuhan, 430030, China.
Regenerative therapy
|April 14, 2025
概括
使用骨髓介质干细胞 (BMSCs) 治疗大肠炎的最佳剂量是5 × 10 ^ 6细胞. 这种剂量可以确保有效地将细胞植入结肠以获得治疗潜力.
科学领域:
- 再生医学是一种再生医学.
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 骨髓介质干细胞 (BMSCs) 显示出对炎症疾病的治疗潜力.
- 确定最佳的BMSC剂量对于有效的细胞移植治疗至关重要.
研究的目的:
- 在大鼠模型中研究骨髓介质干细胞 (BMSCs) 治疗性结肠炎的最佳剂量.
- 评估移植的BMSCs在结肠中的植入和分布.
主要方法:
- 患有诱导性结肠炎的SD大鼠被随机分配到三组,通过尾脉注射接受不同剂量的DAPI标记的BMSC (1 × 10^6,5 × 10^6或1 × 10^7).
- 结肠和周围组织中的BMSC分布在移植后的第7天和第14天使用光显微镜进行评估.
主要成果:
- 所有组的结肠粘膜中都成功检测到了标有DAPI的BMSC.
- 与1×10^6组相比,5×10^6BMSC组显示结肠中的细胞显著增加 (P<0.05).
- 在5 × 10^6和1 × 10^7 BMSC组之间没有观察到细胞数量的显著差异.
结论:
- 剂量为5×10^6个骨髓介质干细胞被认为是治疗性结肠炎的适当剂量.
- 随着时间的推移,人们观察到结肠中细胞密度较高,周围组织密度较低,这表明有针对性的移植.
更多相关视频
相关概念视频
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Bone Marrow Sampling and Transplants
263
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
263
Drugs for Treatment of Ulcerative Colitis in IBD
106
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
106


